GH1 and metabolic dysfunction-associated steatohepatitis: Recent studies have emphasized the fundamental role of GH and insulin-like growth factor 1 (IGF-1) in the pathogenesis of MASH, suggesting their potential as therapeutic strategies to prevent the progression of MASLD to MASH [42,43].